Darapladib is a Potent Lp-PLA2 Inhibitor for Atherosclerosis and Cancer Research
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.